Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Grazia Pennisi, Salvatore Petta, Daniela Cabibi, Quentin M. Anstee, Gian Paolo Caviglia, Olivier Govaere, Fabio M. Vecchio, Fabio M. Vecchio, Fabio M. Vecchio, Chiara Rosso, Antonio Grieco, Paolo Francione, Marco Y W Zaki, Marco Y. W. Zaki, Antonio Liguori, Ramy Younes, Antonio Grieco, Angelo Armandi, Dina Tiniakos, Maria J Garcia BlancoMaria J. Garcia Blanco, Luca Valenti, Ramy Younes, Elisabetta Bugianesi, Dina Tiniakos, Anna L. Fracanzani, Marco Maggioni, Luca Miele, Ezio David, Alastair Burt

Risultato della ricerca: Articlepeer review

Abstract

INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.
Lingua originaleEnglish
pagine (da-a)1289-1292
Numero di pagine4
RivistaTHE AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume115
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2721???
  • ???subjectarea.asjc.2700.2715???

Fingerprint

Entra nei temi di ricerca di 'Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease'. Insieme formano una fingerprint unica.

Cita questo